...
zvra-img

Zevra Therapeutics Inc., Common Stock

ZVRA

NSQ

$9.15

+$0.16

(1.78%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$489.99M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
260.19K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.93
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$4.2 L
$9.76 H
$9.15

About Zevra Therapeutics Inc., Common Stock

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameZVRASectorS&P500
1-Week Return-1.93%-2.12%0.77%
1-Month Return3.86%-2.54%2.65%
3-Month Return25%-6.28%12.3%
6-Month Return93.86%-1.36%13.48%
1-Year Return84.85%9.29%33.47%
3-Year Return12.55%10.05%32.22%
5-Year Return52.91%43.69%92.85%
10-Year Return-94.89%103.1%194.31%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue12.84M13.29M28.65M10.46M27.46M[{"date":"2019-12-31","value":44.81,"profit":true},{"date":"2020-12-31","value":46.38,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":36.5,"profit":true},{"date":"2023-12-31","value":95.85,"profit":true}]
Cost of Revenue2.94M1.30M2.06M343.00K2.94M[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":44.31,"profit":true},{"date":"2021-12-31","value":69.92,"profit":true},{"date":"2022-12-31","value":11.65,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Gross Profit9.89M11.98M26.59M10.12M24.52M[{"date":"2019-12-31","value":37.21,"profit":true},{"date":"2020-12-31","value":45.06,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":38.04,"profit":true},{"date":"2023-12-31","value":92.2,"profit":true}]
Gross Margin77.06%90.18%92.81%96.72%89.28%[{"date":"2019-12-31","value":79.68,"profit":true},{"date":"2020-12-31","value":93.24,"profit":true},{"date":"2021-12-31","value":95.96,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.3,"profit":true}]
Operating Expenses30.23M16.76M18.86M34.96M74.12M[{"date":"2019-12-31","value":40.79,"profit":true},{"date":"2020-12-31","value":22.62,"profit":true},{"date":"2021-12-31","value":25.45,"profit":true},{"date":"2022-12-31","value":47.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Income(20.34M)(4.78M)7.73M(24.84M)(49.60M)[{"date":"2019-12-31","value":-263.13,"profit":false},{"date":"2020-12-31","value":-61.86,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-321.41,"profit":false},{"date":"2023-12-31","value":-641.79,"profit":false}]
Total Non-Operating Income/Expense(10.41M)(14.19M)(16.38M)(1.54M)7.25M[{"date":"2019-12-31","value":-143.63,"profit":false},{"date":"2020-12-31","value":-195.7,"profit":false},{"date":"2021-12-31","value":-225.93,"profit":false},{"date":"2022-12-31","value":-21.22,"profit":false},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(24.54M)(12.79M)(8.52M)(42.33M)(46.05M)[{"date":"2019-12-31","value":-2454400000,"profit":false},{"date":"2020-12-31","value":-1279400000,"profit":false},{"date":"2021-12-31","value":-852100000,"profit":false},{"date":"2022-12-31","value":-4232900000,"profit":false},{"date":"2023-12-31","value":-4604900000,"profit":false}]
Income Taxes(22.00K)(34.00K)34.00K(786.00K)-[{"date":"2019-12-31","value":-64.71,"profit":false},{"date":"2020-12-31","value":-100,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":-2311.76,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income After Taxes(24.52M)(12.76M)(8.55M)(41.54M)-[{"date":"2019-12-31","value":-2452200000,"profit":false},{"date":"2020-12-31","value":-1276000000,"profit":false},{"date":"2021-12-31","value":-855500000,"profit":false},{"date":"2022-12-31","value":-4154300000,"profit":false},{"date":"2023-12-31","value":"-","profit":true}]
Income From Continuous Operations(24.52M)(12.76M)(8.55M)(41.54M)(39.92M)[{"date":"2019-12-31","value":-2452200000,"profit":false},{"date":"2020-12-31","value":-1276000000,"profit":false},{"date":"2021-12-31","value":-855500000,"profit":false},{"date":"2022-12-31","value":-4154300000,"profit":false},{"date":"2023-12-31","value":-3991700000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(24.52M)(12.76M)(8.55M)(41.54M)(46.05M)[{"date":"2019-12-31","value":-2452200000,"profit":false},{"date":"2020-12-31","value":-1276000000,"profit":false},{"date":"2021-12-31","value":-855500000,"profit":false},{"date":"2022-12-31","value":-4154300000,"profit":false},{"date":"2023-12-31","value":-4604900000,"profit":false}]
EPS (Diluted)(11.84)(3.31)(0.46)(0.69)(1.29)[{"date":"2019-12-31","value":-1184,"profit":false},{"date":"2020-12-31","value":-331,"profit":false},{"date":"2021-12-31","value":-46,"profit":false},{"date":"2022-12-31","value":-69,"profit":false},{"date":"2023-12-31","value":-129,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

ZVRA
Cash Ratio 1.57
Current Ratio 2.88
Quick Ratio 2.63

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

ZVRA
ROA (LTM) -32.81%
ROE (LTM) -130.67%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

ZVRA
Debt Ratio Lower is generally better. Negative is bad. 0.64
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.36

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

ZVRA
Trailing PE NM
Forward PE 192.31
P/S (TTM) 20.01
P/B 7.02
Price/FCF NM
EV/R 18.81
EV/Ebitda NM
PEG 10.67

FAQs

What is Zevra Therapeutics Inc. share price today?

Zevra Therapeutics Inc. (ZVRA) share price today is $9.15

Can Indians buy Zevra Therapeutics Inc. shares?

Yes, Indians can buy shares of Zevra Therapeutics Inc. (ZVRA) on Vested. To buy Zevra Therapeutics Inc. from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ZVRA stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Zevra Therapeutics Inc. be purchased?

Yes, you can purchase fractional shares of Zevra Therapeutics Inc. (ZVRA) via the Vested app. You can start investing in Zevra Therapeutics Inc. (ZVRA) with a minimum investment of $1.

How to invest in Zevra Therapeutics Inc. shares from India?

You can invest in shares of Zevra Therapeutics Inc. (ZVRA) via Vested in three simple steps:

  • Click on Sign Up or Invest in ZVRA stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Zevra Therapeutics Inc. shares
What is Zevra Therapeutics Inc. 52-week high and low stock price?

The 52-week high price of Zevra Therapeutics Inc. (ZVRA) is $9.76. The 52-week low price of Zevra Therapeutics Inc. (ZVRA) is $4.2.

What is Zevra Therapeutics Inc. price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Zevra Therapeutics Inc. (ZVRA) is

What is Zevra Therapeutics Inc. price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Zevra Therapeutics Inc. (ZVRA) is 7.02

What is Zevra Therapeutics Inc. dividend yield?

The dividend yield of Zevra Therapeutics Inc. (ZVRA) is 0.00%

What is the Market Cap of Zevra Therapeutics Inc.?

The market capitalization of Zevra Therapeutics Inc. (ZVRA) is $489.99M

What is Zevra Therapeutics Inc.’s stock symbol?

The stock symbol (or ticker) of Zevra Therapeutics Inc. is ZVRA

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top